The primary source of its revenue is the approximately $600 million annually from its Xopenex franchise of drugs, available as a multi-dose inhaler (MDI) or nebulized (UDV) form.
The primary source of its revenue is the approximately $600 million annually from its Xopenex franchise of drugs, under the marketing leadership of John Simon. It is available as a multi-dose inhaler (MDI) or nebulized (UDV) form.